Your browser is no longer supported. Please, upgrade your browser.
HALO Halozyme Therapeutics, Inc. daily Stock Chart
HALO [NASD]
Halozyme Therapeutics, Inc.
Index- P/E- EPS (ttm)-0.27 Insider Own1.10% Shs Outstand135.94M Perf Week8.16%
Market Cap4.26B Forward P/E19.30 EPS next Y1.61 Insider Trans-8.26% Shs Float131.67M Perf Month20.82%
Income-39.70M PEG- EPS next Q0.20 Inst Own- Short Float11.11% Perf Quarter11.03%
Sales180.50M P/S23.60 EPS this Y10.50% Inst Trans-0.72% Short Ratio13.71 Perf Half Y33.36%
Book/sh0.78 P/B39.87 EPS next Y133.82% ROA-8.10% Target Price32.73 Perf Year108.31%
Cash/sh2.81 P/C11.05 EPS next 5Y58.00% ROE-31.70% 52W Range12.71 - 31.64 Perf YTD75.41%
Dividend- P/FCF- EPS past 5Y2.10% ROI-13.70% 52W High-1.71% Beta1.62
Dividend %- Quick Ratio17.30 Sales past 5Y21.10% Gross Margin72.00% 52W Low144.69% ATR0.98
Employees132 Current Ratio19.20 Sales Q/Q41.20% Oper. Margin-16.80% RSI (14)74.20 Volatility3.41% 3.20%
OptionableYes Debt/Eq3.69 EPS Q/Q285.90% Profit Margin-22.00% Rel Volume1.10 Prev Close31.09
ShortableYes LT Debt/Eq3.69 EarningsNov 02 AMC Payout- Avg Volume1.07M Price31.10
Recom2.30 SMA2011.51% SMA5011.70% SMA20031.14% Volume1,178,896 Change0.03%
Sep-14-20Resumed JP Morgan Overweight $28
Jul-01-20Initiated The Benchmark Company Buy $39
Feb-05-20Upgrade Piper Sandler Neutral → Overweight $18 → $27
Jan-09-20Upgrade BMO Capital Markets Market Perform → Outperform $17 → $24
Jan-08-20Initiated Goldman Buy $24
Nov-05-19Upgrade Barclays Underweight → Equal Weight $17 → $16
Oct-19-18Resumed Piper Jaffray Neutral
May-11-18Downgrade Barclays Equal Weight → Underweight $19
Jan-24-18Initiated Goldman Neutral
Oct-16-17Reiterated Piper Jaffray Overweight $26 → $29
Jan-06-17Downgrade Citigroup Buy → Neutral
Nov-03-16Initiated Deutsche Bank Buy $12
Dec-04-15Initiated Wells Fargo Outperform
Nov-18-15Initiated Citigroup Buy
Sep-22-15Initiated Barclays Overweight $27
Jun-22-15Reiterated JP Morgan Overweight $20 → $25
Mar-03-15Reiterated UBS Buy $16 → $21
Feb-18-15Reiterated MLV & Co Buy $15 → $20
Jan-08-15Reiterated MLV & Co Buy $12 → $15
Dec-24-14Initiated MLV & Co Buy $12
Oct-22-20 07:30PM  
Oct-21-20 08:38AM  
Oct-20-20 03:16PM  
Oct-06-20 02:14AM  
Sep-28-20 10:40AM  
Sep-17-20 08:00AM  
Sep-10-20 08:01AM  
Sep-09-20 11:30AM  
08:01AM  
Sep-02-20 04:01PM  
Aug-11-20 11:18AM  
09:00AM  
Aug-10-20 05:25PM  
04:01PM  
Aug-04-20 04:05PM  
Aug-03-20 12:31PM  
Jul-29-20 04:05PM  
Jul-28-20 12:32PM  
Jul-23-20 09:49AM  
Jul-17-20 01:30PM  
Jul-09-20 02:46PM  
Jul-01-20 07:20PM  
Jun-29-20 12:54PM  
Jun-22-20 08:00AM  
Jun-19-20 08:32AM  
Jun-17-20 05:08PM  
Jun-16-20 10:01AM  
Jun-13-20 07:09AM  
Jun-10-20 11:30AM  
Jun-04-20 12:35PM  
May-29-20 10:28AM  
May-28-20 08:01AM  
May-20-20 08:32AM  
May-19-20 08:37AM  
May-15-20 11:25AM  
May-14-20 04:01PM  
May-13-20 03:18AM  
May-12-20 09:52AM  
04:31AM  
May-11-20 06:35PM  
04:01PM  
11:50AM  
May-08-20 10:34AM  
May-07-20 08:01AM  
May-01-20 03:16PM  
Apr-30-20 04:56PM  
Apr-28-20 05:05PM  
12:33PM  
Apr-26-20 09:40PM  
Apr-13-20 08:44AM  
Apr-03-20 08:00AM  
Mar-29-20 05:44PM  
Mar-25-20 11:30AM  
Mar-19-20 10:30AM  
Mar-05-20 06:36PM  
Feb-28-20 08:39AM  
Feb-27-20 07:37AM  
Feb-26-20 04:01PM  
Feb-25-20 10:05AM  
01:20AM  
Feb-24-20 05:45PM  
04:02PM  
04:01PM  
Feb-17-20 12:30PM  
Feb-10-20 04:01PM  
Feb-06-20 08:25AM  
Jan-14-20 08:00AM  
Jan-03-20 08:00AM  
Dec-12-19 11:30AM  
02:00AM  
Dec-06-19 10:02AM  
Nov-20-19 05:28PM  
Nov-15-19 10:09AM  
Nov-14-19 08:27AM  
Nov-13-19 10:57PM  
09:06AM  
Nov-12-19 05:45PM  
04:30PM  
04:10PM  
04:01PM  
Nov-07-19 12:56PM  
Nov-05-19 10:32AM  
Nov-04-19 09:56AM  
07:00AM  
07:00AM  
Nov-01-19 09:05AM  
Oct-23-19 01:30PM  
Oct-21-19 08:00AM  
Oct-02-19 09:14AM  
Sep-23-19 08:00AM  
Sep-13-19 09:44PM  
05:27PM  
01:00AM  
Sep-02-19 10:48AM  
Aug-26-19 08:00AM  
Aug-08-19 10:58AM  
Aug-06-19 06:15PM  
04:01PM  
12:20PM  
Jul-30-19 10:38AM  
Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. Its proprietary product include Hylenex recombinant, a formulation of rHuPH20 to facilitate subcutaneous fluid administration for achieving hydration; to enhance the dispersion and absorption of other injected drugs in subcutaneous urography; and to improve resorption of radiopaque agents. The company is also developing Perjeta for breast cancer; RITUXAN HYCELA and MabThera SC for the treatment of non-Hodgkin lymphoma and chronic lymphocytic leukemia (CLL); RITUXAN SC for patients with CLL; and HYQVIA for the treatment of immunodeficiency disorders. In addition, it is developing Tecentriq for non-small cell lung cancer; OCREVUS for multiple sclerosis; DARZALEX for the treatment of patients with amyloidosis, smoldering myeloma, and multiple myeloma; nivolumab for the treatment of solid tumors; ALXN1210 and ALXN1810 subcutaneous formulations; ARGX-113, a human neonatal Fc receptor; ARGX-117 to treat autoimmune diseases; and BMS-986179, an anti-CD-73 antibody. The company has collaborations with F. Hoffmann-La Roche, Ltd.; Hoffmann-La Roche, Inc.; Baxalta US Inc.; Baxalta GmbH; Pfizer Inc.; Janssen Biotech, Inc.; AbbVie, Inc.; Eli Lilly and Company; Bristol-Myers Squibb Company; Alexion Pharma Holding; ARGENX BVBA; and National Institute of Allergy and Infectious Diseases. Halozyme Therapeutics, Inc. was founded in 1998 and is headquartered in San Diego, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
LaBarre Michael J.SVP, Chief Technical OfficerOct 20Sale30.4312,000365,148146,800Oct 20 04:53 PM
LaBarre Michael J.SVP, Chief Technical OfficerSep 21Sale26.9112,000322,884158,800Sep 21 07:30 PM
MATSUI CONNIEDirectorSep 11Sale27.0632,000865,792216,753Sep 14 05:33 PM
Matsuda MasaruSVP, General CounselSep 04Option Exercise0.006,884013,822Sep 04 06:13 PM
LaBarre Michael J.SVP, Chief Technical OfficerAug 20Sale28.3012,000339,564170,800Aug 20 04:21 PM
Daly James MDirectorAug 13Sale29.1234,337999,89331,365Aug 13 06:43 PM
LaBarre Michael J.SVP, Chief Technical OfficerJul 20Sale29.0112,000348,072182,800Jul 20 06:33 PM
LaBarre Michael J.SVP, Chief Technical OfficerMay 22Option Exercise7.1418,613132,897194,800May 22 06:39 PM
LaBarre Michael J.SVP, Chief Technical OfficerMay 20Option Exercise7.1421,387152,703197,574May 21 04:11 PM
LaBarre Michael J.SVP, Chief Technical OfficerMay 20Sale23.8021,387509,075176,187May 21 04:11 PM
Kelley Kenneth JDirectorMar 19Buy14.2352,629748,697277,553Mar 19 07:28 PM
LaBarre Michael J.SVP, Chief Technical OfficerFeb 22Option Exercise0.008,8030179,231Feb 24 08:04 PM
Stelzer LaurieSVP, Chief Financial OfficerFeb 22Option Exercise0.0011,3920120,675Feb 24 08:03 PM
Torley HelenPresident and CEOFeb 22Option Exercise0.0039,3540510,033Feb 24 08:02 PM
LaBarre Michael J.SVP, Chief Technical OfficerFeb 14Option Exercise0.005,7720172,423Feb 18 04:16 PM
Stelzer LaurieSVP, Chief Financial OfficerFeb 14Option Exercise0.007,8090111,983Feb 18 04:15 PM
Torley HelenPresident and CEOFeb 14Option Exercise0.0028,7300484,923Feb 18 04:14 PM
Matsuda MasaruSVP, General CounselFeb 12Option Exercise0.004,13008,619Feb 13 06:41 PM
LaBarre Michael J.SVP, Chief Technical OfficerFeb 12Option Exercise0.007,8830169,376Feb 13 06:39 PM
Stelzer LaurieSVP, Chief Financial OfficerFeb 12Option Exercise0.0011,2620108,068Feb 13 06:38 PM
Torley HelenPresident and CEOFeb 12Option Exercise0.0032,7950472,452Feb 13 06:24 PM
LaBarre Michael J.SVP, Chief Technical OfficerFeb 03Option Exercise0.0011,5590165,782Feb 04 04:24 PM
Stelzer LaurieSVP, Chief Financial OfficerFeb 03Option Exercise0.0023,1190105,081Feb 04 04:21 PM
Torley HelenPresident and CEOFeb 03Option Exercise0.0055,4870459,567Feb 04 04:18 PM
affiliate | advertise | contact | privacy | help
Do not sell my personal information

Quotes delayed 15 minutes for NASDAQ, and 20 minutes for NYSE and AMEX.
Copyright © 2007-2020 FINVIZ.com. All Rights Reserved.